The research company Aptahem is likely to begin clinical development of Apta-1 within disease areas where inflammation, coagulation and immunological dysregulation interact, CEO Mikael Lindstam says in a newsletter for May.Lindstam highlights acute-on-chronic liver failure (ACLF), acute kidney injury and atypical hemolytic uremic syndrome as possible first indications for the drug candidate. According to the Aptahem chief, the diseases share several pathological characteristics with sepsis, including microvascular coagulation, inflammation and tissue damage.Lindstam further states that the focus is increasingly on securing a strategic development partner to support future clinical activities and accelerate the development of Apta-1."I am convinced that this represents the best opportunity to realize the value in Apta-1 in the long term," he says.